Photo by cdc from unsplash
We read with interest the work of Menard et al. [1] that brings additional knowledge on the neuropsychiatric tolerance of dolutegravir. They also provide pharmacokinetic data which is very welcomed… Click to show full abstract
We read with interest the work of Menard et al. [1] that brings additional knowledge on the neuropsychiatric tolerance of dolutegravir. They also provide pharmacokinetic data which is very welcomed as published works concerning the potential association between neuropsychiatric adverse drug reactions (ADRs) and dolutegravir concentrations are scarce. Their data are in line with other studies that recently reported neuropsychiatric adverse effects in patients receiving dolutegravir-containing regimen in other countries in Europe [2–4].
Journal Title: AIDS
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!